KFAS
DNLI icon

Keating Financial Advisory Services’s Denali Therapeutics DNLI Stock Holding History

Keating Financial Advisory Services’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$634 Buy
33
+13
+65% +$259 ﹤0.01% 2212
2025
Q4 		$330 Buy
+20
New +$338 ﹤0.01% 2008

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Keating Financial Advisory Services's DNLI Position: Q1 2026 in Review

Keating Financial Advisory Services increased its Denali Therapeutics (DNLI) stake by 65% in Q1 2026, buying an estimated $259 and bringing the position to 33 shares worth $634. The position accounts for ﹤0.01% of the portfolio, ranked #2212.

Keating Financial Advisory Services first reported a position in DNLI in Q4 2025 and has held it in 2 quarters since. 268 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Keating Financial Advisory Services held 33 shares of Denali Therapeutics worth $634 as of Q1 2026.
  • Keating Financial Advisory Services bought 13 Denali Therapeutics shares in Q1 2026, an estimated $259.
  • Denali Therapeutics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q1 2026, its #2212 holding.
  • Keating Financial Advisory Services first reported a position in Denali Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 268 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Keating Financial Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.